Contineum Therapeutics Inc (CTNM)

Mar 17, 2025, 4:05 PM EDT - 15 days ago

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Mar 12, 2025, 4:05 PM EDT - 20 days ago

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Mar 6, 2025, 4:05 PM EST - 26 days ago

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Mar 4, 2025, 4:05 PM EST - 4 weeks ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Mar 3, 2025, 4:05 PM EST - 4 weeks ago

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 2 months ago

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Dec 16, 2024, 4:05 PM EST - 3 months ago

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Nov 25, 2024, 8:05 AM EST - 4 months ago

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Nov 18, 2024, 8:05 AM EST - 4 months ago

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Nov 13, 2024, 4:05 PM EST - 4 months ago

Contineum Therapeutics to Attend Upcoming Investor Conferences

Nov 6, 2024, 4:05 PM EST - 5 months ago

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Aug 28, 2024, 4:05 PM EDT - 7 months ago

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 8 months ago

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 31, 2024, 4:05 PM EDT - 8 months ago

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Jun 24, 2024, 4:05 PM EDT - 10 months ago

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

RNA

Jun 13, 2024, 2:03 PM EDT - 10 months ago

Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model

Jun 4, 2024, 4:05 PM EDT - 10 months ago

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 10 months ago

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

May 20, 2024, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

May 16, 2024, 4:05 PM EDT - 11 months ago

Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 6, 2024, 5:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings

JNJ LOAR MAMO PACS RBRK ULS ZBAO

Apr 4, 2024, 9:02 PM EDT - 1 year ago

Contineum Therapeutics Announces Pricing of Initial Public Offering

Mar 15, 2024, 5:39 PM EDT - 1 year ago

Neuroscience and inflammation biotech Contineum Therapeutics files for a $150 million IPO

Mar 15, 2024, 5:04 PM EDT - 1 year ago

Contineum Therapeutics IPO Registration Document (S-1)